Michelle Lynn Tomsho

59484411, Sep 7, 1999

Jan 3, 1995

8/367923

Robert P. Lenk - Lambertville NJ
Anthony G. Durning - Yardley PA
Robert J. Klimchak - Flemington NJ
Joel Portnoff - Richboro PA
Michelle L. Tomsho - Levittown PA

The Liposome Company, Inc. - Princeton NJ

A61K 9127
A61K 914
B01J 1304
B01J 1320

424489

Tangential flow filtration is used in the size separation of particles, such as liposomes and lipid particles. These particles may be passed through a tangential flow filtration device of any pore size desired. Tangential flow filter systems of various pore sizes may be used sequentially to obtain particles such as lipid particles or liposomes having a defined size range.

60249382, Feb 15, 2000

Dec 24, 1997

8/997894

Diane C. Corbo - Flemington NJ
Mary Jean M. Link - Princeton NJ
N. Adeyinka Williams - Doylestown PA
Michelle L. Tomsho - Langhorne PA
Michael Bornstein - Westfield NJ
Howard F. Solomon - New Hope PA
Scott K. Larsen - West Chester PA
Robert L. Suddith - Wilmington NC

Ortho Pharmaceutical Corporation - Raritan NJ
Johnson-Matthey Inc. - West Chester PA

A61K 5100
A61M 3614

424 169

A lyophilized imaging agent formulation and methods for making same are disclosed, such formulations comprise a targeting molecule such as antibody or chemotactic peptide, a linker such as diethylenetriaminepentaacetic acid (DTPA) or succinimidyl 6-hydrazinium nicotinate hydrochloride (SHNH), drying protectant such as mannitol, maltose or tricine, and excipient such as polysorbate 80, in citrate buffer. The formulations of the invention are lyophilized and may be stored stably for extended periods of time. Following reconstitution with diluent, the formulations are administered to a subject for scintigraphic imaging or therapeutic use. Also contemplated is a kit comprising a two-vial system wherein a first vial comprises a lyophilized formulation of imaging agent in the form of a lyophilized cake, and a second vial comprises a pharmaceutically acceptable carrier or diluent.

59253754, Jul 20, 1999

Nov 3, 1994

8/333770

Robert P. Lenk - The Woodland TX
Michelle L. Tomsho - Levittown PA
Robert L. Suddith - Wilmington NC
Robert J. Klimchak - Flemington NJ
Andrew S. Janoff - Yardley PA
Sharma R. Minchey - Monmouth Junction NJ
Marc J. Ostro - Pennington NJ

The Liposome Company, Inc. - Princeton NJ

A61K 9127
A61K 9133

424450

This invention provides a multilamellar liposome containing an arachidonic acid metabolite, two or more lipid-containing bilayers and two or more aqueous compartments containing a release-inhibiting buffer. Preferred arachidonic acid metabolites are the prostaglandins, particularly PGE. sub. 1. The liposomal formulations can be used to treat animals, particularly humans, for diseases, disorders or conditions which can be ameliorated by prostaglandins, e. g. , disorders characterized by cellular activation and adhesion, inflammation and/or toxemia.

52621685, Nov 16, 1993

Jan 16, 1992

7/821648

Robert P. Lenk - Lambertville NJ
Michelle L. Tomsho - Levittown PA
Robert L. Suddith - Robbinsville NJ
Robert J. Klimchak - Flemington NJ

The Liposome Company, Inc. - Princeton NJ

A61K 3722

424450

A liposome composition and methods for making same are disclosed, such compositions comprise an arachidonic acid metabolite such as a prostaglandin, preferably prostaglandin E. sub. 1, a lipid, and a drying protectant such as a saccharide. The liposomes may be loaded with prostaglandin passively, or using a transmembrane concentration gradient, preferably using a transmembrane pH gradient. Using this transmembrane loading technique, trapping efficiencies of 50% to 100% are achieved, and the release rate of the prostaglandin from the liposomes is reduced. The liposome size is maintained after lyophilization and reconstitution.

50826646, Jan 21, 1992

May 18, 1988

7/195228

Robert P. Lenk - Lambertville NJ
Michelle L. Tomsho - Levittown PA
Robert L. Suddith - Robbinsville NJ
Robert J. Klimchak - Flemington NJ

The Liposome Company, Inc. - Princeton NJ

A61K 3722

424450

A liposome composition and methods for making same are disclosed, such compositions comprise an arachidonic acid metabolite such as a prostaglandin, preferably prostaglandin E. sub. 1, a lipid, and a drying protectant such as a saccharide. The liposomes may be loaded with prostaglandin passively, or using a transmembrane concentration gradient, preferably using a transmembrane pH gradient. Using this transmembrane loading technique, trapping efficiencies of 50% to 100% are achieved, and the release rate of the prostaglandin from the liposomes is reduced. The liposome size is maintained after lyophilization and reconstitution.